source
- Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challengesAcquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
- FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefitThe FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…